

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial

Patrick A. Brown, MD; Lingyun Ji, PhD; Xinxin Xu, MS; Meenakshi Devidas, PhD; Laura E. Hogan, MD; Michael J. Borowitz, MD, PhD; Elizabeth A. Raetz, MD; Gerhard Zugmaier, MD; Elad Sharon, MD, MPH; Melanie B. Bernhardt, PharmD; Stephanie A. Terezakis, MD; Lia Gore, MD; James A. Whitlock, MD; Michael A. Pulsipher, MD; Stephen P. Hunger, MD; Mignon L. Loh, MD

IMPORTANCE Standard chemotherapy for first relapse of B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults is associated with high rates of severe toxicities, subsequent relapse, and death, especially for patients with early relapse (high risk) or late relapse with residual disease after reinduction chemotherapy (intermediate risk). Blinatumomab, a bispecific CD3 to CD19 T cell-engaging antibody construct, is efficacious in relapsed/refractory B-ALL and has a favorable toxicity profile.

OBJECTIVE To determine whether substituting blinatumomab for intensive chemotherapy in consolidation therapy would improve survival in children, adolescents, and young adults with high- and intermediate-risk first relapse of B-ALL.

DESIGN, SETTING, AND PARTICIPANTS This trial was a randomized phase 3 clinical trial conducted by the Children's Oncology Group at 155 hospitals in the US, Canada, Australia, and New Zealand with enrollment from December 2014 to September 2019 and follow-up until September 30, 2020. Eligible patients included those aged 1 to 30 years with B-ALL first relapse, excluding those with Down syndrome, Philadelphia chromosome-positive ALL, prior hematopoietic stem cell transplant, or prior blinatumomab treatment (n = 669).

INTERVENTIONS All patients received a 4-week reinduction chemotherapy course, followed by randomized assignment to receive 2 cycles of blinatumomab (n = 105) or 2 cycles of multiagent chemotherapy (n = 103), each followed by transplant.

MAIN OUTCOME AND MEASURES The primary end point was disease-free survival and the secondary end point was overall survival, both from the time of randomization. The threshold for statistical significance was set at a 1-sided $P < .025$.

RESULTS Among 208 randomized patients (median age, 9 years; 97 [47%] females), 118 (57%) completed the randomized therapy. Randomization was terminated at the recommendation of the data and safety monitoring committee without meeting stopping rules for efficacy or futility; at that point, 80 of 131 planned events occurred. With 2.9 years of median follow-up, 2-year disease-free survival was 54.4% for the blinatumomab group vs 39.0% for the chemotherapy group (hazard ratio for disease progression or mortality, 0.70 [95% CI, 0.47-1.03]; 1-sided $P = .03$). Two-year overall survival was 71.3% for the blinatumomab group vs 58.4% for the chemotherapy group (hazard ratio for mortality, 0.62 [95% CI, 0.39-0.98]; 1-sided $P = .02$). Rates of notable serious adverse events included infection (15%), febrile neutropenia (5%), sepsis (2%), and mucositis (1%) for the blinatumomab group and infection (65%), febrile neutropenia (58%), sepsis (27%), and mucositis (28%) for the chemotherapy group.

CONCLUSIONS AND RELEVANCE Among children, adolescents, and young adults with high- and intermediate-risk first relapse of B-ALL, postreinduction treatment with blinatumomab compared with chemotherapy, followed by transplant, did not result in a statistically significant difference in disease-free survival. However, study interpretation is limited by early termination with possible underpowering for the primary end point.

TRIAL REGISTRATION ClinicalTrials.gov Identifier: [NCT02101853](https://clinicaltrials.gov/ct2/show/study/NCT02101853)

JAMA. 2021;325(9):833-842. doi:10.1001/jama.2021.0669

- [+ Visual Abstract](#)
- [← Editorial page 830](#)
- [← Related article page 843](#)
- [+ Supplemental content](#)
- [+ CME Quiz at \[jamacmelookup.com\]\(http://jamacmelookup.com\)](#)

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Patrick A. Brown, MD, Department of Oncology, Johns Hopkins University School of Medicine, 1650 Orleans St, CRB1 Room 2M51, Baltimore, MD 21287 (pbrown2@jhmi.edu).

Survival for children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia (B-ALL) is poor, especially in patients with early relapse, for whom 5-year survival is 25% to 50%.¹⁻⁵ Standard first relapse treatment includes 4 weeks of reinduction chemotherapy followed by consolidation therapy, which includes 2 cycles of intensive multiagent chemotherapy for early bone marrow relapse (<36 months after diagnosis), followed by hematopoietic stem cell transplant.⁶ Many patients with early relapse cannot proceed to transplant due to adverse chemotherapy events, including serious infection,⁷ or inability to achieve the minimal residual disease (MRD)-negative second remission associated with optimal transplant outcomes.^{8,9} For late first bone marrow relapse (≥36 months after diagnosis), MRD greater than or equal to 0.1% after reinduction is associated with poor survival of approximately 50% to 60%,^{10,11} and consolidation therapy consists of intensive chemotherapy and transplant. Patients with late first marrow relapse and MRD less than 0.1% following reinduction have excellent survival with chemotherapy without transplant.¹⁰⁻¹²

Blinatumomab is a bispecific T cell-engaging antibody construct that links CD3+ T cells to CD19+ leukemia cells, inducing a cytotoxic immune response. Blinatumomab is approved by the US Food and Drug Administration for the treatment of adults and children with relapsed/refractory B-ALL,^{13,14} and received accelerated approval for MRD-positive B-ALL,¹⁵ which is conditional on confirmatory trials. This trial (AALL1331) is one of the confirmatory trials and was designed to determine whether substituting blinatumomab for chemotherapy consolidation after 1 cycle of standard reinduction chemotherapy improved disease-free survival in first relapse of B-ALL in children, adolescents, and young adults.

Methods

Trial Oversight

The trial protocol and amendments (eAppendix in [Supplement 1](#)) were approved by the National Cancer Institute Pediatric Central Institutional Review Board and by each trial center's institutional review board. All patients or a parent/guardian provided written informed consent, which included information regarding evolving US Food and Drug Administration approval of blinatumomab. The independent Children's Oncology Group data and safety monitoring committee met regularly to review trial safety and efficacy data according to its charter and standard operating procedures.

Eligibility and Reinduction

Patients aged 1 to 30 years with B-ALL first relapse were eligible. Exclusions included Down syndrome, Philadelphia chromosome-positive ALL, previous transplant, and previous blinatumomab treatment. All patients received 4 weeks of reinduction chemotherapy with vincristine, dexamethasone, pegaspargase, mitoxantrone, and risk-based intrathecal chemotherapy (eTable 1 in [Supplement 2](#)), which is the

Key Points

Question Does immunotherapy with blinatumomab result in longer disease-free survival compared with chemotherapy as postreinduction consolidation therapy prior to hematopoietic stem cell transplant in children, adolescents, and young adults with high- and intermediate-risk first relapse of B-cell acute lymphoblastic leukemia?

Findings In this randomized clinical trial that included 208 patients with high- and intermediate-risk first relapse of B-cell acute lymphoblastic leukemia and was terminated early, treatment with blinatumomab vs chemotherapy resulted in 2-year disease-free survival of 54% vs 39% of participants, but the difference was not statistically significant.

Meaning Postreinduction treatment with blinatumomab compared with chemotherapy, followed by hematopoietic stem cell transplant, did not result in a statistically significant difference in disease-free survival, but study interpretation is limited by early termination with possible underpowering for the primary end point.

regimen used in the mitoxantrone-treated group in the UKALLR3 clinical trial.⁴

Postreinduction Evaluation and Risk Assignment

After reinduction, bone marrow aspiration was evaluated locally for morphologic response and centrally for flow cytometric MRD response (Borowitz laboratory at Johns Hopkins Hospital; sensitivity, 1 in 10 000).¹⁶ Evaluations for patients with central nervous system (CNS) or testicular extramedullary disease included lumbar puncture or testicular examination with biopsy if examination findings were equivocal. Postinduction risk groups were defined as follows: early treatment failure, defined as greater than 25% marrow blasts or failure to clear CNS leukemia; high risk, bone marrow (includes isolated bone marrow and combined bone marrow and extramedullary) relapse less than 36 months after diagnosis or isolated extramedullary relapse less than 18 months after diagnosis; intermediate risk, bone marrow relapse at least 36 months after diagnosis or isolated extramedullary relapse at least 18 months after diagnosis and MRD greater than or equal to 0.1%; and low risk, bone marrow relapse at least 36 months after diagnosis or isolated extramedullary relapse at least 18 months after diagnosis and MRD less than 0.1%.

Because previous studies have shown similar survival in these populations, patients with high- and intermediate-risk relapse were grouped together for randomization.^{10,11} The early treatment failure group was offered nonrandomized salvage therapy with blinatumomab. Herein are results for the high- and intermediate-risk group and for the early treatment failure group. Results for the randomized low-risk group have not yet been released by the data and safety monitoring committee.

Randomization

Following reinduction, individuals in the high- and intermediate-risk group were randomized in a 1:1 ratio to

receive blinatumomab (experimental) or chemotherapy (control). To balance potential confounding factors, randomization was stratified by risk group (high vs intermediate risk), among the high risk group by site of relapse (bone marrow vs isolated extramedullary), and among the high-risk bone marrow relapse group by time from original diagnosis to relapse (<18 vs 18-36 months) and postreinduction MRD (<0.1% vs ≥0.1%).

Treatments and Evaluations

The blinatumomab group underwent 2 continuous 28-day infusion cycles of blinatumomab, 15 µg/m² per day, separated by a 7-day break (eTable 2 in [Supplement 2](#)). The chemotherapy group underwent 2 chemotherapy cycles (4-week cycles), based on the UKALLR3 trial⁴ (eTable 3 in [Supplement 2](#)). Risk-adapted intrathecal therapy was provided to both groups. Response evaluation occurred following completion of each of the 2 cycles of randomized therapy. For flow MRD, the central laboratory was blinded to the treatment group. The MRD assay included a standard panel with CD19 and an additional CD19-independent panel.¹⁷ On completion of randomized therapy, patients underwent transplant. Transplant recommendations and procedures are described in the protocol (eAppendix in the [Supplement 1](#)).

The early treatment failure group was not eligible for randomization, but was eligible to receive up to 2 cycles of blinatumomab salvage therapy (eTable 4 in [Supplement 2](#)) unless they had residual CNS leukemia after reinduction.

Outcomes

The primary end point was disease-free survival, defined as time from randomization to late treatment failure (≥5% marrow blasts after first course of randomized therapy), relapse, second malignancy, or death. Patients without events were censored at their last follow-up date. The secondary end point was overall survival (time from randomization to death from any cause). An exploratory end point was rate of MRD negativity (<0.01%) after each course of randomized therapy. A post hoc end point was rate of proceeding to transplant. Adverse events (AEs) were graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.0), and grade 3 AEs or higher were categorized as severe. Select blinatumomab-related AEs were monitored in blinatumomab cycles 1 and 2, including cytokine release syndrome and neurotoxicity-related AEs, which were subclassified into seizures and encephalopathic AEs, such as cognitive disturbance, tremor, ataxia, or dysarthria.

For patients with early treatment failure who received salvage blinatumomab therapy, an exploratory end point was to estimate the rates of complete remission (<5% marrow blasts), MRD negativity (<0.01%), and proceeding to transplant in remission after salvage blinatumomab.

Race/Ethnicity

To comply with National Institutes of Health requirements, self-declared race/ethnicity data were collected by the researcher at each enrolling site, who chose from predefined

categories for race (American Indian/Alaskan Native; Asian, Native Hawaiian, or other Pacific Islander; Black or African American; White; more than 1 race; and unknown or not reported) and ethnicity (not Hispanic or Latino, Hispanic or Latino, and unknown/not reported).

Statistical Analysis

The expected 2-year disease-free survival for patients with high- and intermediate-risk relapse who received the control treatment was 45%. Consistent with previous Children's Oncology Group ALL trials,^{18,19} an approximate 40% reduction in events was considered to be clinically meaningful. Thus, AALL1331 was designed to detect an improvement to 63% disease-free survival (hazard ratio, 0.58) with 85% power and 1-sided α level of .025 with 110 patients per randomized group, with 2 interim analyses and 1 final analysis. One-sided testing was used because it facilitated efficient futility monitoring. The analysis set was defined as all patients randomized prior to June 30, 2019. Follow-up was current as of September 30, 2020. Patients with missing outcome data were censored at the time of last follow-up (**Figure 1**). Efficacy stopping boundaries were based on the O'Brien-Fleming spending function.^{20,21} Futility boundaries were based on testing the alternative hypothesis at the .024 level.²² AEs were assessed in the as-treated population (randomized patients who received ≥1 dose of the randomized therapy).


The Kaplan-Meier method was used to estimate disease-free survival and overall survival rates, with standard errors assessed with the Greenwood method.²³ A 1-sided stratified log-rank test was used to compare disease-free survival and overall survival between randomized groups, with a significance threshold of 1-sided $P = .025$. Hazard ratios and associated 95% CIs were calculated using stratified Cox proportional hazards models. The proportional hazards assumption was tested using graphical diagnostics and verified based on scaled Schoenfeld residuals.²⁴ Comparisons of categorical variables were performed with Pearson χ^2 tests or Fisher exact tests as appropriate, with a significance threshold of 2-sided $P = .05$. Because of the potential for type I error due to multiple comparisons, findings for analyses of secondary end points should be interpreted as exploratory. Statistical analyses were performed using Stata, version 15.1 (StataCorp).

Results

Early Closure of Randomization

Randomization commenced in January 2015. Following a planned interim analysis in September 2019 using a data cut-off of June 30, 2019, when 80 of 131 (61%) anticipated events occurred, the data and safety monitoring committee recommended the randomization be halted early. The P value for disease-free survival at this time was $P = .06$. The critical P value for the efficacy stopping rule was $P = .004$. Although the disease-free survival efficacy stopping rule was not met, the combination of higher disease-free survival and overall survival, lower rates of serious toxicity, and higher rates

Figure 1. Flow of Patients in a Study of the Effect of Postreinduction Consolidation With Blinatumomab vs Chemotherapy



Patients for whom protocol-specified therapy was stopped for nonevents continued to be followed up for events in the primary analysis.

^a Patients were censored at the time of withdrawal of consent in the analyses.

^b Early treatment failure: >25% marrow blasts or failure to clear central nervous system leukemia; high risk, bone marrow relapse <36 mo or isolated extramedullary relapse <18 mo after diagnosis; intermediate risk, bone marrow relapse ≥36 mo or isolated extramedullary relapse ≥18 mo after diagnosis and minimal residual disease

(MRD) ≥0.1%; and low risk, same as intermediate except MRD <0.1%.

^c Twenty-two given blinatumomab and included in an exploratory analysis.

^d In a 1:1 ratio stratified by risk group, site of relapse, first remission duration, and postreinduction MRD.

^e One proceeded to hematopoietic stem cell transplant (HSCT) after cycle 1.

^f Five patients proceeded to HSCT after cycle 1.

Table 1. Baseline Characteristics of Participants in a Study of the Effect of Postreinduction Consolidation With Blinatumomab vs Chemotherapy in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia

Characteristic	No. (%)	
	Blinatumomab (n = 105)	Chemotherapy (n = 103)
Age at enrollment, y		
Median (IQR)	9 (6-16)	9 (5-16)
1-9	55 (52.4)	55 (53.4)
10-12	10 (9.5)	11 (10.7)
13-17	25 (23.8)	19 (18.4)
18-20	8 (7.6)	10 (9.7)
21-27 ^a	7 (6.7)	8 (7.8)
Age at initial diagnosis, y		
Median (IQR)	6 (3-13)	6 (3-13)
<1	7 (6.7)	10 (9.7)
1-9	56 (53.3)	55 (53.4)
10-12	16 (15.2)	11 (10.7)
13-17	24 (22.9)	18 (17.5)
18-26 ^a	2 (1.9)	9 (8.7)
Sex		
Female	48 (45.7)	49 (47.6)
Male	57 (54.3)	54 (52.4)
Race	n = 83	n = 89
American Indian or Alaska Native	2 (2.4)	0
Asian	4 (4.8)	4 (4.5)
Black or African American	7 (8.4)	18 (20.2)
White	69 (83.1)	66 (74.2)
Multiple	1 (1.2)	1 (1.1)
Ethnicity	n = 97	n = 98
Hispanic or Latino	36 (37.1)	34 (34.7)
Not Hispanic or Latino	61 (62.9)	64 (65.3)
Site of relapse		
Marrow (≥36 mo after diagnosis)	36 (34.3)	34 (33.0)
Marrow (18-36 mo after diagnosis)	41 (39.0)	41 (39.8)
MRD ≥0.1%, No. ^b	19	19
MRD <0.1%, No. ^b	22	21
MRD unknown, No. ^b	0	1 ^c
Marrow (<18 mo after diagnosis)	18 (17.1)	18 (17.5)
MRD ≥0.1%, No. ^b	8	8
MRD <0.1%, No. ^b	9	10
MRD unknown, No. ^b	1 ^d	0
Isolated extramedullary (<18 mo after diagnosis)	10 (9.5)	10 (9.7)
Risk group assignment after reinduction		
High risk	69 (65.7)	69 (67.0)
Intermediate risk	36 (34.3)	34 (33.0)

(continued)

Table 1. Baseline Characteristics of Participants in a Study of the Effect of Postreinduction Consolidation With Blinatumomab vs Chemotherapy in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia (continued)

Characteristic	No. (%)	
	Blinatumomab (n = 105)	Chemotherapy (n = 103)
Cytogenetic group ^e		
Favorable	21 (23.3)	16 (17.6)
ETV6-RUNX1, No.	12	8
Hyperdiploid with +4, +10, No.	9	8
Unfavorable	7 (7.8)	10 (11)
KMT2A-rearranged, No.	7	9
Hypodiploid, No.	0	1
Other	62 (68.9)	65 (71.4)
Unknown, No.	15	12

Abbreviation: IQR, interquartile range.

^a Patients aged up to 30 years were eligible for inclusion; however, no patient enrolled was older than 26 years at initial diagnosis or 27 years at enrollment.^b Minimal residual disease (MRD) is ascertained by assays of blood specimens that use polymerase chain reactions or flow cytometry to detect acute lymphoblastic leukemia cells; MRD is defined by the presence of at least 0.01% acute lymphoblastic leukemia cells in a posttreatment blood specimen and predicts the likelihood of relapse.^c This patient's MRD after reinduction was unsatisfactory. The patient was treated as stratum "high-risk patients (marrow ≥18 to <36 mo; MRD <0.1%)" for randomization.^d This patient's MRD after reinduction was indeterminate due to a strange immunophenotype. The patient was categorized in the high-risk group for randomization.^e Reported by site using indicated categorical choices, which included the "unknown" category, based on cytogenetic results from original diagnosis. The indicated cytogenetic categories were of interest due to their known association with either favorable or unfavorable prognosis in the setting of upfront treatment.

of MRD clearance for blinatumomab relative to chemotherapy prompted the data and safety monitoring committee to recommend closure of the high- and intermediate-risk randomization due to loss of clinical equipoise between the randomized treatments.


Patients and Treatment

A total of 214 patients (of a planned 220 patients) were randomized (107 to each group; Figure 1); 6 patients randomized after June 30, 2019, (2 in the blinatumomab group and 4 in the chemotherapy group) were excluded from analyses because their postrandomization therapy was affected by early randomization closure and crossover of patients in the chemotherapy group to receive blinatumomab. Thus, the final analysis included 208 randomized patients (105 in the blinatumomab group and 103 in the chemotherapy group). The groups were well-balanced in terms of baseline characteristics (Table 1).

Primary End Point: Disease-Free Survival

As of September 30, 2020, the median follow-up among living patients was 2.9 years (range, 0-5.6 years; interquartile range, 1.8-3.9 years) and the 2-year disease-free survival rate

Figure 2. Disease-Free and Overall Survival in a Study of the Effect of Postreinduction Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia



The median (interquartile range) length of follow-up among living patients was 2.9 (1.8-3.9) years for all patients, 3.1 (1.8-3.9) years for the blinatumomab group, and 2.7 (1.7-3.6) years for the chemotherapy group. A, Two-year disease-free survival was 54.4% for the blinatumomab group vs 39.0% for the

chemotherapy group (hazard ratio for disease progression or mortality, 0.70 [95% CI, 0.47-1.03]). B, Two-year overall survival was 71.3% for the blinatumomab group vs 58.4% for the chemotherapy group (hazard ratio for mortality, 0.62 [95% CI, 0.39-0.98]). Tic marks indicate censoring.

Table 2. Outcomes in a Study of the Effect of Postreinduction Consolidation With Blinatumomab vs Chemotherapy in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia

End point	No. (%)		Absolute difference (95% CI), %	Odds ratio (95% CI) ^a	P value ^a
	Blinatumomab (n = 105)	Chemotherapy (n = 103)			
First event (components of the primary end point) ^b					
Late treatment failure ^c	1 (1)	9 (9)	−8 (−14 to −2)		
Relapse	35 (33)	32 (31)	2 (−10 to 15)		
Death	12 (11)	18 (17)	−6 (−16 to 3)		
Exploratory end points ^d					
Negative MRD at the end of reinduction	26 (25)	31 (30)	−5 (−17 to 7)	0.76 (0.4 to 1.5) ^e	.39
Negative MRD at the end of cycle 1	79 (75)	33 (32)	43 (31 to 55)	6.4 (3.4 to 12.4) ^e	<.001
Negative MRD at the end of cycle 2	69 (66)	33 (32)	34 (21 to 46)	4.1(2.2 to 7.6) ^e	<.001
Underwent hematopoietic stem cell transplant ^f	74 (70)	44 (43)	27 (15 to 41)	3.2 (1.7 to 5.9)	<.001

^a Odds ratios and P values are not shown for the comparisons of event rates because these are competing events.

^b All events but 1 took place within 2 years of randomization.

^c Late treatment failure was defined as $\geq 5\%$ blasts in marrow after cycle 1.

^d Minimal residual disease (MRD) is ascertained by assays of blood specimens that use polymerase chain reactions or flow cytometry to detect acute lymphoblastic leukemia cells; MRD is defined by the presence of at least 0.01% acute lymphoblastic leukemia cells in a posttreatment blood specimen and predicts the likelihood of relapse. Negative MRD is defined as MRD less than 0.01%.

^e The odds ratio for negative MRD represents the odds of negative MRD in the blinatumomab group vs the chemotherapy group. In this analysis, positive MRD (defined as MRD $\geq 0.01\%$ or MRD $< 0.01\%$ with sensitivity of 1 in 1000) or no MRD data are considered as not having negative MRD. The rationale for including patients with no MRD data in this analysis is that the lack of MRD data was due to death, relapse, or removal from protocol therapy because of an adverse event or other poor response to therapy, so it is appropriate to include them as the converse of the optimal outcome of being able to submit a sample and have negative MRD.

^f Received transplant without intervening nonprotocol therapy.

was 54.4% for the blinatumomab group vs 39.0% for the chemotherapy group (hazard ratio for disease progression or mortality, 0.70 [95% CI, 0.47-1.03]) (Figure 2A). This difference was not statistically significant (1-sided $P = .03$). First disease-free survival events are shown in Table 2. All first disease-free survival events occurred within 2 years of randomization with 1 exception (1 patient in the blinatumomab group relapsed in month 41), with median time to event of 6 months (range, 8 days to 41 months; interquartile range, 2.2-10.7 months) and no significant differences in event timing be-

tween the groups. Of the 208 randomized patients, 6 (3%) withdrew consent or were lost to follow-up with less than 2 years of follow-up.

Secondary End Point: Overall Survival

The 2-year overall survival rate was 71.3% for the blinatumomab group vs 58.4% for the chemotherapy group (hazard ratio for mortality, 0.62 [95% CI, 0.39-0.98]) (Figure 2B). This difference was statistically significant (1-sided $P = .02$). All deaths occurred within 2 years, with 5 exceptions (3 patients

in the blinatumomab group died in months 31, 34, and 45 and 2 patients in the chemotherapy group died in months 36 and 41, all following earlier relapse).

Exploratory End Point: MRD

The percentages of patients who had detectable MRD prior to and after each cycle of postrandomization therapy are shown in Table 2. There were no significant differences between groups at the time of randomization ($P = .39$). After the first cycle of randomized therapy, the MRD negativity rate was 75% for the blinatumomab group vs 32% for the chemotherapy group (difference, 43% [95% CI, 31%-55%]; $P < .001$). The significant difference in MRD negativity persisted following the second cycle of randomized therapy (66% in the blinatumomab group vs 32% in the chemotherapy group; difference, 34% [95% CI, 21%-46%]; $P < .001$). Compared with the blinatumomab group, the chemotherapy group had more patients with no MRD data (primarily due to death, relapse, or severe AEs). For the blinatumomab group, the MRD negativity percentage dropped between the first (75%) and second (66%) cycles. Of the 15 patients who did not have negative MRD after the first cycle of blinatumomab, 5 (33%) had negative MRD after the second cycle (eTable 5 in Supplement 2). However, of the 79 patients that had negative MRD after the first blinatumomab cycle, 8 (10%) reverted to being MRD-positive and 2 (3%) relapsed after cycle 2 (eTable 6 in Supplement 2). All 10 of these patients had high-risk bone marrow relapse. Of the 8 cases of MRD re-emergence following the second cycle of blinatumomab, 7 were assessable for CD19 expression by flow cytometry and 1 had too few residual cells for characterization. Of these, 3 were CD19-negative (antigen loss) and 4 were CD19-positive. Of the 2 relapses, 1 was CD19-negative and 1 was CD19-positive.

Post Hoc End Point: Proceeding to Transplant

The percentages of patients in each randomized group who began postrandomization therapy and successfully proceeded to transplant without receiving nonprotocol therapy are shown in Table 2. For the blinatumomab group, 70% proceeded to transplant, compared with 43% for the chemotherapy group (difference, 27% [95% CI, 15%-41%]; $P < .001$).

AE End Point

The rates of AEs for the randomized groups are summarized in Table 3, which displays toxicities for each randomized cycle, and in eTable 7 in Supplement 2, which displays cumulative rates for both randomized cycles. The grade 3 and higher AEs with cumulative rates higher than 25% for the blinatumomab group (eTable 7 in Supplement 2) included cytopenias (neutrophils [47%], lymphocytes [40%], and white blood cells [34%]). The grade 3 and higher AEs with cumulative rates higher than 25% for the chemotherapy group (eTable 7 in Supplement 2) included cytopenias (platelets [67%], neutrophils [64%], anemia [62%], white blood cells [61%], and lymphocytes [34%]), febrile neutropenia (58%), increased alanine aminotransferase (41%), mucositis (28%), and sepsis (27%).

Four AEs of special interest were identified based on their known association with life-threatening complications (infection, febrile neutropenia, mucositis, and sepsis). The cumulative rates of these AEs in the blinatumomab group were 15% for infection, 5% for febrile neutropenia, 1% for mucositis, and 2% for sepsis (eTable 7 in Supplement 2). The cumulative rates of these AEs in the chemotherapy group were 65% for infection, 58% for febrile neutropenia, 28% for mucositis, and 27% for sepsis (eTable 7 in Supplement 2). There were 5 toxic deaths during chemotherapy cycles 1 and 2 (all infections) vs none during blinatumomab cycles 1 and 2. Four of the 5 toxic deaths were adolescent and young adult patients (aged 14, 17, 23, and 26 y). The rates of blinatumomab-related AEs of any grade and of greater than or equal to grade 3 were as follows: 22% and 1% in cycle 1 and 1% and 0% in cycle 2 for cytokine release syndrome, 11% and 2% in cycle 1 and 8% and 2% in cycle 2 for encephalopathy, and 4% and 1% in cycle 1 and 1% and 0% in cycle 2 for seizure (Table 3). All blinatumomab-related AEs were fully reversible, with no AE-related deaths. Of 102 patients who underwent cycle 1 and 88 patients who underwent cycle 2 in the blinatumomab group, 19 (19%) and 15 (17%) had a blinatumomab dose reduction based on protocol-specified criteria (eAppendix in Supplement 1).

Subgroup Outcomes

Analyses of disease-free survival, overall survival, MRD, rates of transplant, and events for the high- and intermediate-risk subgroups are shown in the eFigure and eTable 8 in Supplement 2. Analyses of baseline characteristics, disease-free survival, and overall survival for adolescent and young adult (aged 18-30 years) and child (aged <18 years) subgroups are shown in eTable 9 and the eFigure in Supplement 2.

Exploratory End Point: Outcomes for Patients Ineligible for Randomization Due to Early Treatment Failure

A total of 45 patients met criteria for early treatment failure (eTable 10 in Supplement 2) and were not eligible for randomization. Three had persistent CNS disease and were ineligible to receive salvage blinatumomab. Among the 42 patients with early treatment failure who were eligible, 20 pursued other therapies and 22 received salvage blinatumomab. Five of 22 patients (23%) had morphologic remission (<5% marrow blasts) after 1 cycle of salvage blinatumomab. Of these 5 patients, 3 had negative MRD after either 1 cycle ($n = 2$) or 2 cycles ($n = 1$). All 3 patients who had negative MRD proceeded to transplant. The 2 patients who did not have negative MRD did not proceed to transplant in remission.

Discussion

Among children, adolescents, and young adults with high- and intermediate-risk first relapse of B-ALL, postinduction treatment with blinatumomab, compared with chemotherapy, followed by hematopoietic stem cell transplant did not result in a statistically significant difference in disease-free survival. Because the randomization was terminated

Table 3. Adverse Events in a Study of the Effect of Postreinduction Consolidation With Blinatumomab vs Chemotherapy in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia

Adverse event	No. (%)							
	Cycle 1				Cycle 2			
	Blinatumomab (n = 102)		Chemotherapy (n = 97)		Blinatumomab (n = 88)		Chemotherapy (n = 62)	
	Any grade	Grade $\geq 3^a$	Any grade	Grade $\geq 3^a$	Any grade	Grade $\geq 3^a$	Any grade	Grade $\geq 3^a$
Patients with any adverse event	99 (97)	77 (76)	89 (92)	88 (91)	81 (92)	49 (56)	55 (89)	52 (84)
Anemia	77 (76)	15 (15)	63 (65)	51 (53)	39 (44)	4 (5)	36 (58)	35 (57)
White blood cell decreased	67 (66)	25 (25)	59 (61)	55 (57)	50 (57)	13 (15)	30 (48)	30 (48)
Alanine aminotransferase increased	65 (64)	12 (12)	62 (64)	38 (39)	37 (42)	6 (7)	27 (44)	8 (13)
Fever	54 (53)	6 (6)	24 (25)	5 (5)	20 (23)	2 (2)	20 (32)	6 (10)
Neutrophil count decreased	51 (50)	34 (33)	58 (60)	57 (59)	43 (49)	25 (28)	32 (52)	31 (50)
Aspartate aminotransferase increased	49 (48)	9 (9)	51 (53)	14 (14)	26 (30)	1 (1)	24 (39)	3 (5)
Hypoalbuminemia	47 (46)	0	43 (44)	6 (6)	18 (21)	0	23 (37)	1 (2)
Lymphocyte count decreased	43 (42)	37 (36)	32 (33)	30 (31)	33 (38)	18 (21)	16 (26)	15 (24)
Platelet count decreased	43 (42)	8 (8)	63 (65)	56 (58)	18 (21)	3 (3)	37 (60)	34 (55)
Hyperglycemia	32 (31)	2 (2)	24 (25)	6 (6)	31 (35)	2 (2)	19 (31)	8 (13)
Hypocalcemia	31 (30)	2 (2)	36 (37)	6 (6)	12 (14)	0	18 (29)	0
Hypokalemia	28 (28)	7 (7)	36 (37)	19 (20)	21 (24)	2 (2)	28 (45)	14 (23)
Hypophosphatemia	18 (18)	0	18 (19)	5 (5)	8 (9)	0	7 (11)	2 (3)
Hypotension	16 (16)	1 (1)	11 (11)	7 (7)	12 (14)	3 (3)	7 (11)	4 (7)
Blood bilirubin increased	15 (15)	2 (2)	31 (32)	7 (7)	4 (5)	0	16 (26)	2 (3)
Infection ^{b,c}	15 (15)	10 (10)	48 (49)	39 (40)	20 (23)	9 (10)	42 (68)	38 (61)
Vomiting	14 (14)	0	20 (21)	2 (2)	15 (17)	1 (1)	13 (21)	4 (7)
GGT increased	12 (12)	4 (4)	9 (9)	5 (5)	5 (6)	1 (1)	3 (5)	1 (2)
Anorexia	11 (11)	4 (5)	15 (16)	12 (12)	6 (7)	2 (2)	8 (13)	4 (7)
Febrile neutropenia ^b	6 (6)	5 (5)	43 (44)	43 (44)	0	0	28 (45)	28 (45)
Mucositis oral ^b	4 (4)	0	44 (45)	25 (26)	2 (2)	1 (1)	16 (26)	5 (8)
Sepsis ^b	1 (1)	1 (1)	13 (13)	13 (13)	2 (2)	2 (2)	14 (23)	14 (23)
Typhlitis	0	0	1 (1)	1 (1)	0	0	4 (7)	4 (7)
Blinatumomab-related adverse event								
Cytokine release syndrome ^d	22 (22)	1 (1)	NA	NA	1 (1)	0	NA	NA
Encephalopathy	11 (11)	2 (2)	NA	NA	7 (8)	2 (2)	NA	NA
Seizure	4 (4)	1 (1)	NA	NA	1 (1)	0	NA	NA

Abbreviation: NA, not applicable.

^a Grading was performed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.0). Grading ranges from 1 to 5, with 3 indicating severe or medically significant but not immediately life-threatening; 4, life-threatening and indicating urgent intervention; and 5, death. Grades were assigned by the treating physician and select serious adverse events, as defined in the protocol, are reported per federal guidelines.

^b These 4 adverse events of special interest were identified based on their known association with life-threatening complications.

^c Includes catheter-related, lung, skin, upper respiratory tract, and urinary tract infections.

^d Cytokine release syndrome is a toxicity caused by rapid release of cytokines into the blood known to occur with immunotherapies including blinatumomab. Signs and symptoms of cytokine release syndrome include fever, nausea, headache, rash, tachycardia, hypotension, and tachypnea.

early by the independent data and safety monitoring board, the primary analysis set included 208 patients instead of the planned 220, so it is possible that the trial was underpowered for the primary endpoint of disease-free survival.

Patients with early treatment failure with at least 25% marrow blasts after reinduction chemotherapy were not eligible for randomization, but were eligible to receive up to 2 blinatumomab cycles. Based on the experience of the 22 patients with early treatment failure who were non-randomly assigned to receive blinatumomab therapy, the success rate in the salvage setting was low. This outcome supports findings of previous studies that identified high

bone marrow blast percentage as a risk factor for blinatumomab resistance.^{13,14}

The recommendation of early termination of the high- and intermediate-risk randomization was based not on the triggering of the predefined disease-free survival-based or adverse event-based stopping rule, but rather on a combined assessment of disease-free survival and the predefined secondary and exploratory end points of overall survival, MRD, and comparative adverse event profiles, all of which favored blinatumomab over chemotherapy. The data and safety monitoring committee concluded that the totality of data demonstrated a loss of clinical equipoise.

To our knowledge, this is the first randomized trial suggesting a survival benefit for immunotherapy in patients with B-ALL. The TOWER study of adults with relapsed or treatment-refractory ALL showed increased median survival duration from 4 months with chemotherapy to 7.7 months with blinatumomab, but there was no statistically significant difference in overall survival.¹³ Similarly, the INO-VATE randomized study, including adults with relapsed/refractory B-ALL, of the anti-CD22 immunoconjugate inotuzumab showed increased median survival duration but no difference in survival.²⁵ Nonrandomized trials of blinatumomab for adults with MRD-positive B-ALL and of CD19 chimeric antigen receptor T cells in patients aged 3 to 25 years with relapsed/refractory B-ALL showed improved overall survival, but are limited by historical control comparisons.^{15,26}

The goal of treatment for participants in this trial was to provide a “bridge” to stem cell transplant, which is necessary to achieve durable remission. Trial participants treated with blinatumomab had higher rates of becoming MRD-negative and lower rates of AEs than the group treated with chemotherapy, which may explain the higher percentage of participants who were able to continue to transplant. The survival benefit of blinatumomab compared with chemotherapy is likely derived from the percentage of patients who were able to undergo transplant. This trial was designed for all patients to receive 2 cycles of either chemotherapy or blinatumomab followed by transplant. Given the high rate of MRD negativity after cycle 1 of blinatumomab and because some patients who had negative MRD after the first blinatumomab cycle reverted to having positive MRD after the second cycle, future trials should test proceeding directly to transplant after 1 blinatumomab cycle for patients that have MRD negativity. Conversely, continuation of blinatumomab for a second cycle may be appropriate in patients with MRD positivity, because one-third of these patients had MRD negativity after the second cycle of blinatumomab.

The efficacy of blinatumomab relative to chemotherapy for patients with low-risk relapsed B-ALL who are not treated with transplant is not yet known. Study results for the low-risk cohort in this trial will be informative, but have not yet been released by the data and safety monitoring committee.

This trial included patients aged 18 to 30 years, which accounted for 16% of the randomized participants. The UKALLR3 study, the model for the control chemotherapy treatment in this trial, only included patients aged 18 years and younger.⁴ Although the current trial demonstrates the feasibility of incorporating young adults into pediatric cooperative group relapse ALL trials, it also highlights the challenge of greater chemotherapy-related toxicity in young adults.

Limitations

This study has several limitations. First, the disease-free survival comparison is underpowered due to early termination of the high- and intermediate-risk randomization. Second, interpretation of the secondary, exploratory, and post hoc end points is limited by the lack of planned adjustment for multiple comparisons. Third, the transplant procedures (eg, donor, preparatory regimen) were not fully standardized or prescribed, and thus varied among trial participants.

Conclusions

Among children, adolescents, and young adults with high- and intermediate-risk first relapse of B-ALL, postinduction treatment with blinatumomab, compared with chemotherapy, followed by transplant did not result in a statistically significant difference in disease-free survival. However, study interpretation is limited by early termination with possible underpowering for the primary end point.

ARTICLE INFORMATION

Accepted for Publication: January 16, 2021.

Author Affiliations: Departments of Oncology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland (Brown); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (Ji); Children's Oncology Group, Monrovia, California (Xu); Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, Tennessee (Devidas); Department of Pediatrics, Stony Brook Children's, Stony Brook, New York (Hogan); Departments of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland (Borowitz); Department of Pediatrics, NYU Langone Health, New York, New York (Raetz); Amgen Research (Munich), GmbH, Munich, Germany (Zugmaier); Division of Cancer Treatment and Diagnosis, National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, Maryland (Sharon); Section of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas (Bernhardt); University of Minnesota, Department of Radiation Oncology,

Minneapolis (Terezakis); University of Colorado School of Medicine and Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora (Gore); Hospital for Sick Children and University of Toronto, Toronto, Canada (Whitlock); Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Diseases Institute, Los Angeles, California (Pulsipher); Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia and The Perelman School of Medicine at The University of Pennsylvania, Philadelphia (Hunger); Department of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (Loh).

Author Contributions: Drs Brown and Ji had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Hunger and Loh are co-senior authors.

Concept and design: Brown, Ji, Devidas, Borowitz, Raetz, Zugmaier, Sharon, Bernhardt, Terezakis, Gore, Whitlock, Pulsipher, Hunger, Loh.

Acquisition, analysis, or interpretation of data: Brown, Xu, Devidas, Hogan, Borowitz, Sharon, Gore, Pulsipher, Hunger, Loh.

Drafting of the manuscript: Brown, Ji, Xu, Devidas, Sharon, Pulsipher, Hunger.

Critical revision of the manuscript for important intellectual content: Brown, Hogan, Borowitz, Raetz, Zugmaier, Sharon, Bernhardt, Terezakis, Gore, Whitlock, Pulsipher, Hunger, Loh.

Statistical analysis: Brown, Ji, Xu, Devidas.

Obtained funding: Borowitz, Sharon.

Administrative, technical, or material support: Brown, Borowitz, Sharon, Bernhardt, Gore, Pulsipher, Hunger, Loh.

Supervision: Brown, Raetz, Zugmaier, Sharon, Terezakis, Gore, Whitlock, Pulsipher, Loh.

Other - patient contribution: Gore.

Conflict of Interest Disclosures: Dr Brown reported receiving personal fees from serving on scientific advisory committees for Novartis, Kura, Kite, Amgen, Servier, Jazz Pharmaceuticals, and Janssen outside the submitted work. Dr Borowitz reported providing consultancy for Amgen and receiving honoraria from Beckman Coulter. Dr Raetz reported receiving research funding from

Pfizer and serving on a data and safety monitoring board for Celgene outside the submitted work. Dr Zugmaier reported receiving personal fees from Amgen for employment outside the submitted work and having patents pending (10696744, 10662243, 20190142846, 20190127465, 10130638, 20170327581, 9688760, 20170122947, 9486475, 20160208001, 9192665, 20150071928, 8840888, 20140228316, 20140227272, 20130287778, 20130287774, 20100112603, and 7700299) and issued (20190300609, 20110262440, and 20130323247). Dr Bernhardt reported receiving grants from Celgene and Bristol Myers Squibb and personal fees from Servier and Mesoblast outside the submitted work. Dr Terezakis reported receiving grants from ASEL outside the submitted work. Dr Gore reported providing consultancy for Amgen, Novartis, and Roche/Genentech; having equity ownership in Amgen, Blueprint Medicines, Celgene, Clovis, Mirati, and Sanofi Paris; receiving honoraria from Amgen and Roche/Genentech; and serving on a scientific advisory committee for Amgen and data safety and monitoring committees for Novartis and Celgene. Dr Whitlock reported receiving personal fees from Amgen honorarium for consulting outside the submitted work. Dr Pulsipher reported serving on scientific advisory committees for Novartis, Adaptive, and CSL Behring; providing consultancy for Novartis, Jazz Pharmaceuticals, Bellicum Pharmaceuticals, and Mesoblast; and receiving research funding from Adaptive and Miltenyi and honoraria from Amgen and Medac. Dr Hunger reported consulting for Amgen, Bristol Myers Squibb, and Novartis; having equity ownership in Amgen; and receiving honoraria from Jazz Pharmaceuticals outside the submitted work. Dr Loh reported serving on a scientific advisory committee for MediSix Therapeutics outside the submitted work. No other disclosures were reported.

Funding/Support: This clinical trial was funded by grants from the National Institutes of Health/ National Cancer Institute (National Clinical Trials Network Operations Center grant U10CA180886 and National Clinical Trials Network Statistics and Data Center grant U10CA180899) and the St Baldrick's Foundation. Blinatumomab was provided to study participants by Amgen via a Collaborative Research and Development Agreement with the National Institutes of Health/ National Cancer Institute/ Cancer Therapy and Evaluation Program.

Role of the Funder/Sponsor: The Children's Oncology Group investigators designed the trial. The National Cancer Institute (NCI) Cancer Therapy Evaluation Program, Amgen, and the US Food and Drug Administration reviewed the trial, made recommendations for changes, and approved the final trial design. All amendments were reviewed and approved by the NCI and Amgen. The Children's Oncology Group investigators conducted the trial and performed the collection, management, analysis, and interpretation of the data. The first and second authors (P.A.B. and L.J.) prepared the manuscript. All authors, the NCI, and Amgen reviewed and approved the manuscript. The decision to submit the manuscript for publication was made by the authors.

Data Sharing Statement: See Supplement 3.

REFERENCES

1. Nguyen K, Devidas M, Cheng SC, et al; Children's Oncology Group. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. *Leukemia*. 2008;22(12):2142-2150. doi:10.1038/leu.2008.251
2. Horton TM, Whitlock JA, Lu X, et al. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. *Br J Haematol*. 2019;186(2):274-285. doi:10.1111/bjh.15919
3. Raetz EA, Cairo MS, Borowitz MJ, et al. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children's Oncology Group (COG) study ADVL04P2. *Pediatr Blood Cancer*. 2015;62(7):1171-1175. doi:10.1002/pbc.25454
4. Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. *Lancet*. 2010;376(9757):2009-2017. doi:10.1016/S0140-6736(10)62002-8
5. Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. *J Clin Oncol*. 2010;28(14):2339-2347. doi:10.1200/JCO.2009.25.1983
6. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. *Blood*. 2012;120(14):2807-2816. doi:10.1182/blood-2012-02-265884
7. Oskarsson T, Soderhall S, Arvidson J, et al. Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2018;65(4). doi:10.1002/pbc.26909
8. Pulsipher MA, Carlson C, Langholz B, et al. IgH-V(D)J NGS-MRD measurement pre- and early post-allo-transplant defines very low- and very high-risk ALL patients. *Blood*. 2015;125(22):3501-3508. doi:10.1182/blood-2014-12-615757
9. Bader P, Salzmann-Manrique E, Balduzzi A, et al. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. *Blood Adv*. 2019;3(21):3393-3405. doi:10.1182/bloodadvances.2019000449
10. Lew G, Chen Y, Lu X, et al. Outcomes after late bone marrow and very early central nervous system relapse of childhood B-Acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433. *Haematologica*. 2021;106(1):46-55. doi:10.3324/haematol.2019.237230
11. Eckert C, Groeneveld-Krentz S, Kirschner-Schwabe R, et al; ALL-REZ BFM Trial Group. Improving stratification for children with late bone marrow B-cell acute lymphoblastic leukemia relapses with refined response classification and integration of genetics. *J Clin Oncol*. 2019;37(36):3493-3506. doi:10.1200/JCO.19.01694
12. Parker C, Krishnan S, Hamadeh L, et al. Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. *Lancet Haematol*. 2019;6(4):e204-e216. doi:10.1016/S2352-3026(19)30003-1
13. Kantarjian H, Stein A, Gökbuğut N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. *N Engl J Med*. 2017;376(9):836-847. doi:10.1056/NEJMoa1609783
14. von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. *J Clin Oncol*. 2016;34(36):4381-4389. doi:10.1200/JCO.2016.67.3301
15. Gökbuğut N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. *Blood*. 2018;131(14):1522-1531. doi:10.1182/blood-2017-08-798322
16. Borowitz MJ, Devidas M, Hunger SP, et al; Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. *Blood*. 2008;111(12):5477-5485. doi:10.1182/blood-2008-01-132837
17. Cherian S, Miller V, McCullough V, Dougherty K, Fromm JR, Wood BL. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy. *Cytometry B Clin Cytom*. 2018;94(1):112-120. doi:10.1002/cyto.b.21482
18. Dunsmore KP, Winter SS, Devidas M, et al. Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. *J Clin Oncol*. 2020;38(28):3282-3293. doi:10.1200/JCO.20.00256
19. Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group study AALL0232. *J Clin Oncol*. 2016;34(20):2380-2388. doi:10.1200/JCO.2015.62.4544
20. Lan KKG, Demets DL. Discrete sequential boundaries for clinical trials. *Biometrika*. 1983;70(3):659-663. doi:10.1093/biomet/70.3.659
21. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. *Biometrics*. 1979;35(3):549-556. doi:10.2307/2530245
22. Freidlin B, Korn EL. A comment on futility monitoring. *Control Clin Trials*. 2002;23(4):355-366. doi:10.1016/S0197-2456(02)00218-0
23. Kalbfleisch JD, Prentice RL. *The Statistical Analysis of Failure Time Data*. 2nd ed. John Wiley & Sons; 2002.
24. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. *Biometrika*. 1994;81(3):515-526. doi:10.1093/biomet/81.3.515
25. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. *N Engl J Med*. 2016;375(8):740-753. doi:10.1056/NEJMoa1509277
26. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med*. 2018;378(5):439-448. doi:10.1056/NEJMoa1709866